Sign In
Buy BVXV
$1.36
+0 (+0%)
At Close: Dec 05, 2023
BiondVax Announces First Quarter 2020 Financial Results
08:01pm, Tuesday, 30'th Jun 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its f
BVXV: Positive Results in NIH-Sponsored Phase 2 Trial of M-001; Raising Valuation to $81…
12:57pm, Tuesday, 16'th Jun 2020
By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Topline Results from Phase 3 Trial of M-001 Expected by End of 2020 BiondVax Pharmaceuticals, Ltd. (NASDAQ:BVXV) is a
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
12:00pm, Friday, 12'th Jun 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its f
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
11:00am, Wednesday, 10'th Jun 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced the completion of the clinical study report (CSR) of a Phase 2 clinical trial of the Company's M-001 universal influenza vaccine candidate.
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
12:00am, Friday, 22'nd May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 21)
ADC Therapeutics SA (NYSE:...
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
12:00am, Thursday, 21'st May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs on May 20.)
ADC Therapeutics SA (...
BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants
10:30am, Wednesday, 20'th May 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M‑001 universal influenza vaccine candidate, today announced receipt of proceeds of approximately $4.2 million since January 1, 2020 th
May 19, 2020 (AmericaNewsHour) --
United States Influenza Vaccines market is set to touch US$ 3.5 Billion threshold by 2025. "United States Influenza...
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 18)
ADC Therapeutics SA (NYSE:...
How BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Can Impact Your Portfolio Volatility
12:47pm, Saturday, 09'th May 2020
If you own shares in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) then it's worth thinking about how it contributes to...
BiondVax Announces Upcoming Expiration of Public Warrants
10:30am, Monday, 04'th May 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal influenza vaccine candidate M-001, today published a reminder that its publicly traded warrants (traded on Nasdaq under the sym
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs May 1.) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * AstraZe
Could the flu become history? An Israeli vaccine may make it a reality
04:51am, Friday, 01'st May 2020
***
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs May 1.)
Arcturus Therapeutics Ltd (...
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
11:19am, Thursday, 30'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceu
